Related Experiment Video
Updated: Jun 21, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Newer biomarkers in heart failure
Sachin Gupta1, Mark H Drazner, James A de Lemos
1The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Heart Failure Clinics
|July 28, 2009
Summary
Newer heart failure biomarkers like osteoprotegerin and galectin-3 offer insights into disease mechanisms. However, more research is needed before these novel biomarkers can be used in clinical practice for heart failure patients.
Area of Science:
- Cardiology
- Biomarker Discovery
- Heart Failure Pathophysiology
Background:
- Heart failure pathophysiology involves complex mechanisms.
- The number of biomarkers for heart failure is rapidly expanding.
- Understanding these biomarkers is crucial for improved diagnostics and treatment.
Purpose of the Study:
- To review promising newer biomarkers for heart failure.
- To discuss their contribution to understanding pathophysiologic mechanisms.
- To highlight the need for further research on their clinical utility.
Main Methods:
- Literature review focusing on novel heart failure biomarkers.
- Analysis of current data on osteoprotegerin, galectin-3, cystatin C, chromogranin A, and adipokines (adiponectin, leptin, resistin).
- Assessment of the potential role and limitations of these biomarkers.
Main Results:
- Several newer biomarkers show potential in elucidating heart failure mechanisms.
- Osteoprotegerin, galectin-3, cystatin C, chromogranin A, adiponectin, leptin, and resistin are among the promising markers.
- Currently, insufficient data exists for routine clinical application of these novel biomarkers.
Conclusions:
- Emerging biomarkers provide valuable insights into heart failure pathophysiology.
- Significant additional research is required to validate these markers.
- Their future role in heart failure diagnostic and treatment algorithms remains to be determined.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...